VIDEO: New option arises for young women with hormone-sensitive breast cancer

CHICAGO – The aromatase inhibitor exemestane is more effective than tamoxifen in preventing breast cancer recurrence in premenopausal women also receiving ovarian function suppression as adjuvant treatment for hormone-sensitive early breast cancer.

These results, taken from a combined analysis of the TEXT (Tamoxifen and Exemestane Trial) and SOFT (Suppression of Ovarian Function Trial) studies, were presented in a late-breaking abstract at the annual meeting of the American Society of Clinical Oncology.

Click here for our interview with study cochair Dr. Olivia Pagani, breast unit clinical director at the Oncology Institute of Southern Switzerland in Bellinzona.

The trials were supported by the International Breast Cancer Study Group, Pfizer, Ipsen, and the National Cancer Institute. Dr. Pagani reports research support from Ipsen and Pfizer.

[email protected]

CHICAGO – The aromatase inhibitor exemestane is more effective than tamoxifen in preventing breast cancer recurrence in premenopausal women also receiving ovarian function suppression as adjuvant treatment for hormone-sensitive early breast cancer.

These results, taken from a combined analysis of the TEXT (Tamoxifen and Exemestane Trial) and SOFT (Suppression of Ovarian Function Trial) studies, were presented in a late-breaking abstract at the annual meeting of the American Society of Clinical Oncology.

Click here for our interview with study cochair Dr. Olivia Pagani, breast unit clinical director at the Oncology Institute of Southern Switzerland in Bellinzona.

The trials were supported by the International Breast Cancer Study Group, Pfizer, Ipsen, and the National Cancer Institute. Dr. Pagani reports research support from Ipsen and Pfizer.

[email protected]

CHICAGO – The aromatase inhibitor exemestane is more effective than tamoxifen in preventing breast cancer recurrence in premenopausal women also receiving ovarian function suppression as adjuvant treatment for hormone-sensitive early breast cancer.

These results, taken from a combined analysis of the TEXT (Tamoxifen and Exemestane Trial) and SOFT (Suppression of Ovarian Function Trial) studies, were presented in a late-breaking abstract at the annual meeting of the American Society of Clinical Oncology.

Click here for our interview with study cochair Dr. Olivia Pagani, breast unit clinical director at the Oncology Institute of Southern Switzerland in Bellinzona.

The trials were supported by the International Breast Cancer Study Group, Pfizer, Ipsen, and the National Cancer Institute. Dr. Pagani reports research support from Ipsen and Pfizer.

[email protected]